Koers Perrigo Company PLC TEL AVIV STOCK EXCHANGE
Aandelen
IE00BGH1M568
Farmaceutische producten
Omzet 2024 * | 4,66 mld. 1.726 mld. 4,33 mld. | Omzet 2025 * | 4,86 mld. 1.802 mld. 4,52 mld. | Marktkapitalisatie | 4,44 mld. 1.646 mld. 4,13 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -51 mln. -18,9 mld. -47,39 mln. | Nettowinst (verlies) 2025 * | 105 mln. 38,9 mld. 97,58 mln. | EV/omzet 2024 * | 1,64 x |
Nettoschuld 2024 * | 3,19 mld. 1.183 mld. 2,97 mld. | Nettoschuld 2025 * | 3,06 mld. 1.132 mld. 2,84 mld. | EV/omzet 2025 * | 1,54 x |
K/w-verhouding 2024 * |
-44,9
x | K/w-verhouding 2025 * |
121
x | Werknemers | - |
Dividendrendement 2024 * |
3,35% | Dividendrendement 2025 * |
3,57% | Vrij verhandelbaar | 99,69% |
Recentste transcriptie over Perrigo Company PLC
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 55 | 30-06-23 | |
Eduardo Bezerra
DFI | Director of Finance/CFO | 49 | 16-05-22 |
Alison Ives
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-15 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Orlando Ashford
CHM | Chairman | 55 | 15-12-20 |
Jeffrey Kindler
BRD | Director/Board Member | 68 | 06-02-17 |
Bradley Alford
BRD | Director/Board Member | 67 | 06-02-17 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+26,08% | 662 mld. | |
+21,85% | 546 mld. | |
-4,77% | 359 mld. | |
+16,97% | 323 mld. | |
+5,69% | 290 mld. | |
+13,68% | 234 mld. | |
+3,65% | 198 mld. | |
-11,12% | 194 mld. | |
+8,08% | 167 mld. |